KZR Stock Overview
A clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. More details
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
Kezar Life Sciences, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$6.05 |
52 Week High | US$11.35 |
52 Week Low | US$5.20 |
Beta | 0.19 |
1 Month Change | -4.57% |
3 Month Change | -18.24% |
1 Year Change | -37.60% |
3 Year Change | -95.85% |
5 Year Change | -88.23% |
Change since IPO | -96.59% |
Recent News & Updates
Recent updates
Is Kezar Life Sciences (NASDAQ:KZR) Using Debt Sensibly?
Dec 08FDA clears Kezar Life Sciences' drug application for autoimmune hepatitis treatment
Oct 03Is Kezar Life Sciences (NASDAQ:KZR) Using Too Much Debt?
Aug 15Kezar Life Sciences GAAP EPS of -$0.25 beats by $0.02
Aug 11Kezar Life Sciences: Regulatory Tailwinds Reverse Downside Case
Jul 27Kezar Life Sciences appoints Nick Mordwinkin as chief business officer
Jul 11We're Not Very Worried About Kezar Life Sciences' (NASDAQ:KZR) Cash Burn Rate
Jan 03Here's Why We're Not Too Worried About Kezar Life Sciences' (NASDAQ:KZR) Cash Burn Situation
Aug 26We're Not Very Worried About Kezar Life Sciences' (NASDAQ:KZR) Cash Burn Rate
Apr 05Here's What Kezar Life Sciences, Inc.'s (NASDAQ:KZR) Shareholder Ownership Structure Looks Like
Mar 01Kezar Life Sciences, Inc. (NASDAQ:KZR) Insiders Increased Their Holdings
Jan 25Kezar Life Sciences (NASDAQ:KZR) Is In A Good Position To Deliver On Growth Plans
Dec 21Kezar Life Sciences selected for the Nasdaq Biotechnology Index
Dec 14Shareholder Returns
KZR | US Biotechs | US Market | |
---|---|---|---|
7D | 2.5% | -0.5% | -3.9% |
1Y | -37.6% | -7.8% | 16.7% |
Return vs Industry: KZR underperformed the US Biotechs industry which returned -4.4% over the past year.
Return vs Market: KZR underperformed the US Market which returned 17.8% over the past year.
Price Volatility
KZR volatility | |
---|---|
KZR Average Weekly Movement | 5.4% |
Biotechs Industry Average Movement | 10.8% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 17.7% |
10% least volatile stocks in US Market | 3.1% |
Stable Share Price: KZR has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: KZR's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2015 | 58 | Chris Kirk | www.kezarlifesciences.com |
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company’s lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics.
Kezar Life Sciences, Inc. Fundamentals Summary
KZR fundamental statistics | |
---|---|
Market cap | US$45.09m |
Earnings (TTM) | -US$95.78m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.5x
P/E RatioIs KZR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
KZR income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$72.35m |
Gross Profit | -US$72.35m |
Other Expenses | US$23.42m |
Earnings | -US$95.78m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -13.13 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 7.7% |
How did KZR perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/02/25 01:46 |
End of Day Share Price | 2025/02/25 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Kezar Life Sciences, Inc. is covered by 7 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Raghuram Selvaraju | H.C. Wainwright & Co. |
Maurice Raycroft | Jefferies LLC |
Catherine Novack | JonesTrading Institutional Services, LLC |